Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14074428 | 0.85 | BRD4 (0.38) | KDM4EMAPTALDH1A1SMN1; SMN2RECQL | |
| SCHEMBL4873352 | 0.84 | KMT2A (0.47) | KDM4EMAPTALDH1A1SMN1; SMN2PKM | |
| SCHEMBL4863860 | 0.81 | POLB (0.48) | ALDH1A1SMN1; SMN2PKMKMT2AHTR6 | |
| SCHEMBL4869134 | 0.76 | CA2 (0.56) | ALDH1A1GAAKMT2AMEN1HTT | |
| SCHEMBL13045690 | 0.75 | KDM4E (0.47) | KDM4EMAPTALDH1A1SMN1; SMN2RECQL | |
| SCHEMBL18770212 | 0.75 | ALDH1A1 (0.43) | KDM4EALDH1A1SMN1; SMN2PDE4APDE4B | |
| SCHEMBL4872482 | 0.74 | MMP1 (0.51) | KDM4EALDH1A1SMN1; SMN2RECQLPKM | |
| SCHEMBL4873295 | 0.73 | ALDH1A1 (0.50) | KDM4EALDH1A1SMN1; SMN2PKMGAA | |
| SCHEMBL4869169 | 0.70 | ALDH1A1 (0.46) | KDM4EMAPTALDH1A1PKMGAA | |
| SCHEMBL24170274 | 0.70 | CCR8 (0.47) | KDM4EMAPTALDH1A1POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7419967-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419967-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419967-B2 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2006-08-03 | — | — | US | disclosed |
| EP-1086076-B1 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMA (US) | 2004-12-22 | — | — | EP | disclosed |
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | HALE MICHAEL ROBIN (US) | 2004-05-20 | — | — | US | disclosed |
| US-6613743-B2 | Administering to a patient suffering from viral infections a sulfonamides antiviral agents which are aspartyl protease inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2003-09-02 | — | — | US | disclosed |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED | 2002-04-25 | — | — | US | disclosed |
| EP-1086076-A1 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | Vertex Pharmaceuticals Incorporated (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-1999065870-A2 | SULFONAMIDE INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097594-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | KDM4E 1492/4885MAPT 1933/4885ALDH1A1 1841/4885 |
| US-20060172936-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | KDM4E 1492/4885MAPT 1933/4885ALDH1A1 1841/4885 |
| US-20020049201-A1 | Sulfonamide inhibitors of aspartyl protease | SPINT2, PRSS1, DNPEP | KDM4E 1492/4885MAPT 1933/4885ALDH1A1 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.